Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study
Status:
Withdrawn
Trial end date:
2017-08-18
Target enrollment:
Participant gender:
Summary
Primary Objective:
• To collect post-approval safety data related to intraocular pressure (IOP) after one or
more injections of Iluvien as standard of care in subjects with diabetic macular edema (DME).
Secondary Objectives:
• To collect visual and anatomic outcome data after one or more injections of Iluvien as
standard of care in subjects with diabetic macular edema (DME).